What is the official website of Seeker Health by EVERSANA ?

The official website of Seeker Health by EVERSANA is https://www.eversana.com/products/seeker-health/.

What is Seeker Health by EVERSANA's cybersecurity risk score?

Seeker Health by EVERSANA has an AI-generated cybersecurity risk score of 753 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has Seeker Health by EVERSANA experienced?

According to Rankiteo, Seeker Health by EVERSANA currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has Seeker Health by EVERSANA been affected by any supply chain cyber incidents ?

According to Rankiteo, Seeker Health by EVERSANA has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does Seeker Health by EVERSANA have SOC 2 Type 1 certification ?

According to Rankiteo, Seeker Health by EVERSANA is not certified under SOC 2 Type 1.

Does Seeker Health by EVERSANA have SOC 2 Type 2 certification ?

According to Rankiteo, Seeker Health by EVERSANA does not hold a SOC 2 Type 2 certification.

Does Seeker Health by EVERSANA comply with GDPR ?

According to Rankiteo, Seeker Health by EVERSANA is not listed as GDPR compliant.

Does Seeker Health by EVERSANA have PCI DSS certification ?

According to Rankiteo, Seeker Health by EVERSANA does not currently maintain PCI DSS compliance.

Does Seeker Health by EVERSANA comply with HIPAA ?

According to Rankiteo, Seeker Health by EVERSANA is not compliant with HIPAA regulations.

Does Seeker Health by EVERSANA have ISO 27001 certification ?

According to Rankiteo,Seeker Health by EVERSANA is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does Seeker Health by EVERSANA operate in ?

Seeker Health by EVERSANA operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does Seeker Health by EVERSANA have ?

Seeker Health by EVERSANA employs approximately 0 people worldwide.

Does Seeker Health by EVERSANA own any subsidiaries ?

Seeker Health by EVERSANA presently has no subsidiaries across any sectors.

How many LinkedIn followers does Seeker Health by EVERSANA have ?

Seeker Health by EVERSANA's official LinkedIn profile has approximately 678 followers.

What is the NAICS classification code for Seeker Health by EVERSANA ?

Seeker Health by EVERSANA is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does Seeker Health by EVERSANA have a Crunchbase profile ?

No, Seeker Health by EVERSANA does not have a profile on Crunchbase.

Does Seeker Health by EVERSANA have a LinkedIn profile ?

Yes, Seeker Health by EVERSANA maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/seeker-health-by-eversana.

How many cybersecurity incidents has Seeker Health by EVERSANA experienced ?

As of June 30, 2026, Rankiteo reports that Seeker Health by EVERSANA has experienced 1 cybersecurity incidents.

How many peer or competitor companies does Seeker Health by EVERSANA have ?

Seeker Health by EVERSANA has an estimated 5,696 peer or competitor companies worldwide.

What types of cybersecurity incidents has Seeker Health by EVERSANA faced ?

Incident Types: The types of cybersecurity incidents that have occurred include Breach.

NEWRankiteo Cyber Underwriting Desktop - Score, price, and bind from your desktop

WindowsmacOSLinux

Download

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

SHE

Boost Score +25 with badge (5 left)

753

/1000

Fair

778

/1000

Fair

Seeker Health by EVERSANA Vendor Cyber Rating & Cyber Score

eversana.com

Add Your Compliance Badge

Seeker Health by EVERSANA is a digital health patient finding platform that helps biopharmaceutical companies accelerate drug development for serious conditions. Through a wide array of digital strategies, we find patients, and connect them to clinical trials, disease databases, market research and disease awareness efforts.

SHE A.I CyberSecurity Scoring

Scoring History

SHE

Seeker Health by EVERSANA CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

Seeker Health by EV...

Breach

4/2019

EVE238072625

Loading…

A.I.

SHE Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for SHE

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Seeker Health by EVERSANA in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for Seeker Health by EVERSANA in 2026.

Incident Types SHE vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Seeker Health by EVERSANA in 2026.

Incident History - SHE (X = Date, Y = Severity)

Loading…

SUBSIDIARY

Seeker Health by EVERSANA Subsidiaries

SHE

Pharmaceutical Manufacturing

Website: https://www.eversana.com/products/seeker-health/

Company Size: 0

EVERSANAPharmaceutical Manufacturing

EVERSANA ENGAGEPharmaceutical Manufacturing

NAVLIN by EVERSANAPharmaceutical Manufacturing

NAVLIN Price & Access DataPharmaceutical Manufacturing

EVERSANA INTOUCHAdvertising Services

Loading…

Seeker Health by EVERSANA Similar Companies

Ipca Laboratories Limited

ipca.com

A consumer-led global pharmaceutical company, creating healthy doses of life since 1949. When you operate in an industry like pharmaceuticals, your work goes way beyond creating ‘products for customers’. It is different from any other domain – there lies a higher sense of responsibiliti and a need for utmost integriti in everything you do. As you serve millions of lives, high qualiti standards become a pre-requisite, and safeti of your people and consumers always comes first. All this, while ensuring that each life you touch is treated with respect and digniti. For more than 60 years, Ipca has been a crucial healthcare partner in over 120 countries across the 6 continents. We are a fully-integrated pharmaceutical company that manufactures over 350 formulations and 80 APIs for various therapeutic segments. Today, we are one of the world’s largest manufacturers and suppliers of over a dozen APIs. These are produced from scratch at fully-automated manufacturing facilities, approved by the world’s most discerning drug regulatory authorities like UK-MHRA, EDQM-Europe, and WHO-Geneva, among others. - One of the largest suppliers of these APIs worldwide with manufacturing leadership in over 12 APIs globally - 15 APIs & 11 Formulations manufacturing facility across the globe Leader in DMARDs (Disease Modifying Anti-Rheumatic Drugs) treatment for Rheumatoid Arthritis - Leading brands in Pain, Rheumatology, Antimalarials and Hair care therapy - 4 formulations rank amongst the top 300 brands of IPM as per IQVIA

Hikma Pharmaceuticals

cb hikma.com

For almost 50 years, we’ve been creating high-quality medicines and making them accessible to the people who need them. We are a trusted, reliable partner and dependable source of over 800* high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe. We have 29 manufacturing plants, 3 R&D hubs and c9,500 employees worldwide. *As of December 2025 Subscribe to our channel on YouTube https://youtube.com/@hikmapharmaceuticals5668 For all product information and enquiries, please contact us at [email protected]

AUROBINDO PHARMA LTD

aurobindo.com

Aurobindo Pharma Limited (NSE: AUROPHARMA, BSE: 524804, Reuters: ARBN.NS, Bloomberg: ARBP IN) is an integrated global pharmaceutical company headquartered in Hyderabad, India. The Company develops, manufactures, and markets a wide range of generic pharmaceuticals, branded specialty drugs, and active pharmaceutical ingredients (APIs) across more than 150 countries. It is ranked among the top 10 generic companies in eight European nations and holds the distinction of being the largest generic pharmaceutical company in the United States. With over 30 state-of-the-art manufacturing and packaging facilities approved by leading global regulatory authorities including USFDA, UK MHRA, EDQM, Japan PMDA, WHO, Health Canada, South Africa MCC, and Brazil ANVISA, Aurobindo Pharma ensures the highest standards of quality. Its robust portfolio spans eight major therapeutic areas: Central Nervous System (CNS), Antiretroviral (ARV), Cardiovascular (CVS), Antibiotics, Gastroenterology, Anti-diabetics, Oncology, and Dermatology, supported by a strong R&D infrastructure that drives innovation, affordability, and accessibility.

Teva Pharmaceuticals

tevapharm.com

Teva Pharmaceuticals is a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva’s commitment has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients’ needs, now and in the future. At Teva, We Are All In For Better Health. To learn more about how we make it happen, visit www.tevapharm.com. Our community guidelines may be found here: https://www.tevapharm.com/news-and-media/teva-social-media-guidelines/ Please note that adverse effects for any of our products should be reported at: https://www.tevapharm.com/teva-medical-information/report-a-side-effect-form/ Product-specific questions should be directed to Teva or Teva Group subsidiaries in your country. Contact details and Teva's Pharmacovigilance Privacy Policy may be found here: http://www.tevapharm.com/contact_us/

Novo Nordisk

novonordisk.com

We’re not your typical healthcare company. In a modern world of quick fixes, we focus on solutions to defeat serious chronic disease and create long-term health. Our unordinary mindset is at the heart of everything we do. We seek out new ideas and put people first as we push the boundaries of science, make healthcare more accessible, and work to treat, prevent, and even cure diseases that affect millions of lives. Founded in Denmark in 1923, today we employ more than 77,000 people in 80 offices around the world – all united by our bold purpose to drive change to defeat serious chronic diseases. Want to learn more? Visit www.novonordisk.com. This page isn’t intended for discussions about products. As such, postings or comments that contain product discussions may be removed. This page is for discussions about Novo Nordisk and its subsidiaries and the initiatives and projects we are involved in. While we welcome everyone to make comments, we reserve the right to block and remove those that are off-topic, abusive or intended to spam. Any questions specific to products should be made to your healthcare professional. If you wish to file an adverse drug reaction please contact Novo Nordisk’s office in the country you live in: https://www.novonordisk.com/contact-us/find-local-information.html For other customer complaints, please contact us here: https://www.novonordisk.com/contact-us.html Please keep in mind that Novo Nordisk A/S and its subsidiaries work within a highly regulated industry. Therefore, comments that pertain to legal matters or regulatory issues may be removed. Comments contained on this site come from members of the public, and do not necessarily reflect the views of Novo Nordisk A/S. Novo Nordisk A/S does not endorse or approve any content added by other LinkedIn users. Learn more about our privacy disclaimer and community guidelines here: https://www.novonordisk.com/data-privacy-and-user-rights/social-media-privacy-disclaimer.html

Eli Lilly and Company

lilly.com

We're a medicine company turning science into healing to make life better for people around the world. It all started nearly 150 years ago with a clear vision from founder Colonel Eli Lilly: "Take what you find here and make it better and better." Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing science to solve some of the world's most significant health challenges. General Information and Guidelines: When you engage with us on LinkedIn, you're agreeing to these Community Guidelines: https://e.lilly/guidelines. If you have questions about a Lilly medicine, contact The Lilly Answers Center at 1-800-Lilly-Rx (1-800-545-5979) Monday through Friday, excluding company holidays.

Servier

servier.com

Founded to serve health 70 years ago, Servier is a global pharmaceutical group governed by a non-profit Foundation that aspires to make a meaningful social impact for patients and for a sustainable world. The Group’s unique governance model preserves its independence and means it can fully serve its vocation of being committed to therapeutic progress to serve patient needs while adopting a long-term vision. Its employees are fully committed to this shared vocation, which serves as a source of inspiration every day. A world leader in cardiometabolism and venous diseases, Servier has made a major shift into oncology, which represents a new pillar of strategic growth. The Group devotes close to 70% of its R&D budget to this field, with the ambition of becoming a focused and innovative player in the development of treatments targeting rare cancers. Neurology will constitute a future growth driver. Servier is focusing on a limited number of diseases in this area where accurate patient profiling makes it possible to offer a targeted therapeutic response through precision medicine. To promote widespread access to quality care at a lower cost, the Group also offers a range of quality generic drugs covering most pathologies, leveraging well-known brands in France, and Eastern Europe. In all these areas, the Group takes patient considerations into account at every stage of the medicine life cycle. Headquartered in France, Servier relies on committed teams and strong geographical footprint; its medicines are available in close to 140 countries. In 2023/2024, the Group achieved sales revenue of €5.9 billion and EBITDA of €1.3 billion in 2024 (22.2%). Today, the Group employs over 22,000 people worldwide. -- To report a suspected adverse event with a Servier drug, please visit servier.com

Takeda

cb takeda.com

We strive to transform lives. While the science we advance is constantly evolving, our core purpose is enduring. For more than two centuries, our values have guided us to do what’s right for patients and for society. We know that changing lives requires us to do things differently. We start by listening to and addressing what really matters to patients, the people who love them, and those in the healthcare system who provide care. And that’s what inspires us all to be bold, push boundaries and set new standards that open up greater opportunities. Read our community guidelines: https://takeda.info/communityguidelines

MENARINI Group

menarini.com

The Menarini Group is a leading international pharmaceutical and diagnostics company, present in 140 countries worldwide, with a turnover of 4,37 Billion euro and more than 17,000 employees. With 9 centers for Research & Development, Menarini’s products are present in the most important therapeutic areas, including cardiology, oncology, gastroenterology, pneumology, infectious diseases, diabetes, and anti-inflammatory/analgesics. The Group’s pharmaceutical production is carried out in its 18 manufacturing plants, which produce over 609 million packets of product a year and distribute them to five continents. Menarini’s pharmaceutical production, in line with the highest quality standards, provides an ongoing contribution to the health of patients all over the world. For further information, please visit www.menarini.com For reading our Netiquette, please visit https://www.menarini.com/en-us/data-privacy/netiquette-of-menarini-group For reading our Privacy Notice for social networks users, please visit https://www.menarini.com/en-us/data-privacy/privacy-notice-for-social-network-users-of-menarini-group

Loading…

NEWS

Seeker Health by EVERSANA CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-8023

SUMMARY

Zephyr's HTTP server (subsys/net/lib/http) provides a static-filesystem resource type (HTTP_RESOURCE_TYPE_STATIC_FS, available when CONFIG_FILE_SYSTEM is enabled) that serves files from a configured root directory. Before this fix, both the HTTP/1 and HTTP/2 front-ends placed the raw, attacker-controlled request path into client-url_buffer (assembled in on_url() for HTTP/1 and copied verbatim from the :path pseudo-header for HTTP/2) without resolving ./.. segments. The static-FS handler then built the on-disk filename by directly concatenating the configured root with that raw URL (snprintk(fname, ..., "%s%s", static_fs_detail-fs_path, client-url_buffer) at http_server_http1.c:603 and http_server_http2.c:490) and opened it with fs_open(fname, FS_O_READ). Because the handler is reached via wildcard/leading-dir (fnmatch FNM_LEADING_DIR) or fallback resource matching, a request such as GET /<prefix/../../<file is dispatched to the handler and, after the underlying filesystem (e.g. LittleFS/FAT) resolves the .. segments, escapes the configured web root, letting an unauthenticated remote client read arbitrary readable files on the mounted volume (information disclosure). The HTTP server requires no TLS or authentication to reach this path. The fix adds http_server_remove_dot_segments(), which canonicalizes the path portion of the URL before resource lookup in both protocol handlers, neutralizing the traversal. Affects releases v4.0.0 through v4.4.0 for deployments that register a static-filesystem resource.

Published

Date2026-06-29

Updated

Date2026-06-29

RISK INFORMATION (Score: 7.5)

cvss3

Base Score: 7.5

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:H/I:N/A:N

Impact Score

3.6

Exploitability

3.9

REFERENCES

CVE-2026-7656

SUMMARY

The IPv6 Neighbor Discovery handlers in subsys/net/ip/ipv6_nbr.c (handle_ra_input, handle_ns_input, handle_na_input) used an incorrect boolean expression that combined the RFC 4861 validity checks with the ICMPv6 code check using the wrong operator precedence: the form was '((length/hop/source/target checks) && (icmp_hdr-code != 0))'. Because every legitimate ND message carries ICMPv6 code 0, an attacker setting code == 0 (the normal value) caused the entire predicate to evaluate false, so the packet was never dropped and all of the other checks were silently skipped. The bypassed checks include the mandatory Hop Limit == 255 verification (which proves an ND packet originated on-link and was not forwarded) and, for Router Advertisements, the requirement that the source be a link-local address, as well as multicast-target sanity checks. As a result, an adjacent on-link attacker — and, because the Hop-Limit-255 guard is bypassed, potentially a remote/off-link attacker whose packets would otherwise be rejected — can have forged Router Advertisement, Neighbor Solicitation, and Neighbor Advertisement messages accepted. A forged RA lets the attacker reconfigure the victim's default router, on-link prefixes (SLAAC), MTU, reachable/retransmit timers, and (with CONFIG_NET_IPV6_RA_RDNSS) DNS servers, while forged NS/NA enable neighbor-cache poisoning, enabling man-in-the-middle, traffic redirection, and denial of service. The flaw is an input-validation/authentication weakness rather than a memory-safety issue: the underlying packet-parsing primitives (net_pkt_get_data, net_pkt_read, net_pkt_skip) are independently bounds-safe and the validated 'length' is the true buffer length, so skipping the length check causes no out-of-bounds access. The defect has existed since the logic was introduced in 2018 and shipped in all releases through v4.4.0; it is fixed by splitting the condition so any failing check drops the packet.

Published

Date2026-06-29

Updated

Date2026-06-29

RISK INFORMATION (Score: 8.1)

cvss3

Base Score: 8.1

Complexity: LOW

CVSS:3.1/AV:A/AC:L/PR:N/UI:N/S:U/C:N/I:H/A:H

Impact Score

5.2

Exploitability

2.8

REFERENCES

CVE-2026-51219

SUMMARY

A heap buffer overflow in the HighPriorityASDUQueue_hasUnconfirmedIMessages function of lib60870 v2.3.3 to v2.3.6 allows attackers to cause a Denial of Service (DoS) via a crafted payload.

Published

Date2026-06-29

Updated

Date2026-06-29

RISK INFORMATION (Score: )

Impact Score

Exploitability

REFERENCES

CVE-2026-51218

SUMMARY

A heap buffer overflow in the TS7Worker::PerformFunctionWrite() function (/core/s7_server.cpp) of snap7 v1.4.3 allows attackers to cause a Denial of Service (DoS) via a crafted packet.

Published

Date2026-06-29

Updated

Date2026-06-29

RISK INFORMATION (Score: )

Impact Score

Exploitability

REFERENCES

CVE-2026-10648

SUMMARY

mcumgr_serial_process_frag() in subsys/mgmt/mcumgr/transport/src/serial_util.c calls net_buf_reset() on the result of smp_packet_alloc() before checking it for NULL. smp_packet_alloc() uses net_buf_alloc(K_NO_WAIT) against the shared MCUmgr packet pool (CONFIG_MCUMGR_TRANSPORT_NETBUF_COUNT, default 4), which returns NULL when the pool is exhausted. In default builds the __ASSERT_NO_MSG in net_buf_reset is a no-op, so net_buf_simple_reset writes through the NULL pointer (buf->len = 0; buf->data = buf->__buf), causing a fault/crash. The fragment data reaches this code from attacker-controlled bytes on the MCUmgr serial/UART/shell-console transports (smp_uart.c, smp_raw_uart.c, smp_shell.c), and a fresh buffer is allocated at the start of essentially every new packet. An attacker on the serial/console link can flood the transport to drive the 4-entry buffer pool to exhaustion and induce the NULL dereference, crashing the device (denial of service). The defect was introduced after the original MCUmgr rework and shipped in Zephyr v4.4.0. The fix moves the NULL check ahead of net_buf_reset.

Published

Date2026-06-29

Updated

Date2026-06-29

RISK INFORMATION (Score: 6.2)

cvss3

Base Score: 6.2

Complexity: LOW

CVSS:3.1/AV:L/AC:L/PR:N/UI:N/S:U/C:N/I:N/A:H

Impact Score

3.6

Exploitability

2.5

REFERENCES

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…